Clinical trial · Observational
Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status
NCT05634551CI-TRIAL-00079528completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To better understand your feelings and expectations about immunotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interview | Behavioral | — | UNRESOLVED |
| Questionnaires | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Questionnaires (All Participants)
- description
- If participants are found to be eligible and agree to take part in the study, information about you (such as age, gender, race, ethnicity, marital status, education, employment status, religious beliefs, and information about your cancer diagnosis and history, current therapy and goal of cancer therapy) will be collected.
- interventionNames
- Behavioral: Questionnaires
- label
- Interview (Some Participants)
- description
- Not every participant will be asked to have an interview. It is expected that about 20-30 participants will take part in the interview part of the study.
- interventionNames
- Behavioral: Interview
Primary outcomes (1)
- measure
- Discrepancy in expectation of survival for 2 years or more between the patient and oncologist
- timeFrame
- through study completion; an average of 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients being considered for or within 2 months of starting immunotherapy for advanced cancer 2. Patient ≥18 years of age 3. ECOG ≥2 4. Cognitively able to understand consent and complete questionnaire as determined by the interviewer at the time of study enrollment 5. English speaking 6. Willing to participate in the study and sign informed consent 7. The study will include medical oncologists that treat advanced cancers Exclusion Criteria: 1. Treatment for curative intent 2. Presence of Delirium (as determined by score \>13 on MDAS 46, appendix A)
References
Publications (0)
Data not yet available
No reference posted for this study.